Summary of Adverse Events and Safety Parameters Through Safety Follow-Up 4 Weeks After Treatment Discontinuation Parameter Tirzepatide Insulin lispro (n = 708) 15 mg (n = 236) 10 mg (n = 238) 5m g (n = 243) Pooled (n = 717) Participants with ≥1 serious adverse eventa 15 (6.4) 14 (5.9) 15 (6.2) 44 (6.1) 77 (10.9) Deathb 1 (0.4) 3 (1.3) 3 (1.2) 7 (1.0) 11 (1.6) Adverse event leading to study treatment discontinuation 3 (1.3) 4 (1.7) 5 (2.1) 12 (1.7) 15 (2.1) Participants with ≥1 adverse event leading to study treatment discontinuation 22 (9.3) 11 (4.6) 10 (4.1) 43 (6.0) 17 (2.4) Nausea 6 (2.5) 1 (0.4) 3 (1.2) 10 (1.4) 0 Vomiting 5 (2.1) 0 0 5 (0.7) 0 Weight decreased 2 (0.8) 0 0 2 (0.3) 0 Pancreatic enzymes increased 2 (0.8) 1 (0.4) 0 3 (0.4) 0 Decreased appetite 1 (0.4) 1 (0.4) 0 2 (0.3) 0 Dyspepsia 1 (0.4) 1 (0.4) 0 2 (0.3) 0 Gastritis 1 (0.4) 1 (0.4) 0 2 (0.3) 0 Acute coronary syndrome 1 (0.4) 0 0 1 (0.1) 0 COVID-19 0 0003 (0.4) Death 0 0 1 (0.4) 1 (0.1) 1 (0.1) Diarrhea 0 0 2 (0.8) 2 (0.3) 0 Lung neoplasm malignant 0 0002 (0.3) Acute kidney injury 0 1 (0.4) 0 1 (0.1) 0 Participants with ≥1 treatment-emergent adverse eventc 177 (75.0) 168 (70.6) 170 (70.0) 515 (71.8) 394 (55.6) 